The complex contract research market is the focus of BioKansas’ symposium “Access to Research and Infrastructure: The Contract Research Industry.”
LBG’s DJ Rezac, Ph.D. and Kyle Kappeler, Ph.D., who have been invited by BioKansas to participate in the event, will join industry leaders to explore a variety of topics on April 27 – 28 at Kansas State University – Olathe. LBG is one of the sponsors of the symposium.
Dr. Rezac will moderate a panel discussion titled “Advancing Business Objectives in a Changing Market” on April 27 at 11:15 a.m.
The panel will address contemporary issues in the CRO industry, including market consolidation, costs and budgets, timelines, and supply challenges.
“By uniting key opinion leaders and decision-makers in the CRO industry with sponsors seeking their services, this session will provide valuable insight to all stakeholders about the contemporary challenges and opportunities in the space,” says Dr. Rezac.
Dr. Kappeler will give a presentation titled “A Buyer’s Guide for Navigating the Current Contract Research Organization Landscape” on April 27 at 9:30 a.m.
During his presentation, he will share firsthand perspective on different types of CROs (small, large, government, commercial), which he learned while he was a Study Director and Director of Toxicology. He will also address the importance of proper due diligence when selecting a CRO to conduct the nonclinical safety studies and how consultants can make life easier based on their experience and relationships with the vendors.
“My goal is to shed light on the variety of CROs and show potential clients (large and small) that having a valuable partner (LBG) can help them navigate the CRO selection process and CRO interactions, based on company budgets and the CRO area of expertise,” says Dr. Kappeler.
Dr. Rezac provides subject matter and technical expertise, strategic consulting, and business and regulatory team support to a broad portfolio of sponsors, contract research organizations, and academic institutions, as well as federal, state, and local government agencies. He brings a diverse range of experience along the pathway to approval, including in-depth knowledge of exploratory and pivotal study design, execution, and management, with a keen aptitude and unique skill set for supporting programs for defense medical countermeasures, bio and agro-defense, nonclinical safety and efficacy, and complete regulatory path for veterinary pharmaceuticals and biologics.
Dr. Kappeler has more than 10 years of subject matter expertise in preclinical toxicology and safety support for IND/NDA, Global Registration, Food Safety Assessment, Companion Animal, and Animal Rule submissions in accordance with FDA, OECD, U.S. EPA, ICH and/or EFSA guidelines. He possesses an expert understanding of non-GLP and GLP-compliant (21 CRF Part 58) preclinical program design and costing, protocol development, program management, study monitoring/execution, report generation, and SEND management.
The event will also offer opportunities to explore industry trends and tour local CRO facilities.
